The SEAS data were presented today at the European Society of Cardiology, but the focus turned to the cancer risks observed in the trial. An analysis of ongoing studies--IMPROVE-IT and SHARP--suggests the finding is a play of chance, but others, including prominent New England Journal of Medicine editorialists, say there is uncertainty about the safety and efficacy of the drug. Heartwire ...
Anytime
